SCHEMBL787560

SCHEMBL787560

NCCC1=NC(=O)NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8741732 0.73
SCHEMBL538399 0.65
SCHEMBL9422395 0.64
SCHEMBL5070284 0.59
SCHEMBL4434007 0.58
SCHEMBL535025 0.56
SCHEMBL11345853 0.56
SCHEMBL3657135 0.55
SCHEMBL3928670 0.55
SCHEMBL2618034 0.53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2814921-A1 MIXTURES OF OLEFIN-ESTER COPOLYMER WITH POLYOLEFIN AS VISCOSITY MODIFIER The Lubrizol Corporation (US) 2014-12-24 EP claimed
WO-2013123160-A1 MIXTURES OF OLEFIN-ESTER COPOLYMER WITH POLYOLEFIN AS VISCOSITY MODIFIER THE LUBRIZOL CORPORATION (US) 2013-08-22 WO claimed
EP-2245117-B1 BITUMINOUS COMPOSITIONS CECA SA (FR) 2012-04-25 EP claimed
EP-2093274-B1 Bituminous compositions CECA SA (FR) 2011-07-27 EP claimed
EP-2678349-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2014-01-01 EP disclosed
EP-2616441-A2 PYRIDINE COMPOUNDS AND THE USES THEREOF Purdue Pharma LP (US) 2013-07-24 EP disclosed
WO-2012115256-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-30 WO disclosed
WO-2012035421-A2 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA L.P. (US) 2012-03-22 WO disclosed
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 EP disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 EP disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 WO disclosed
WO-2002081466-A1 PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES SUGEN, INC. (US) 2002-10-17 WO disclosed
EP-0594596-A1 COPOLYMERIZABLE IMIDAZOLIDINONE MONOMER H.B. FULLER LICENSING &amp; FINANCING, INC. (US) 1994-05-04 EP disclosed
WO-1991012243-A2 COPOLYMERIZABLE IMIDAZOLIDINONE MONOMER H.B. FULLER LICENSING & FINANCING INC. (US) 1991-08-22 WO disclosed